Astrazeneca (AZN) Short-term Investments (2009 - 2026)

Astrazeneca has reported Short-term Investments for 18 years, with the latest figure at $394.0 million in Q2 2026.

• On a quarterly basis, Short-term Investments fell 22.59% year-over-year to $394.0 million in Q2 2026; TTM through Jun 2026 was $394.0 million, a 22.59% decrease from a year earlier, with the FY2025 full-year figure at $498.0 million, up 173.63% from the prior year.
• Short-term Investments was $394.0 million for Q2 2026 at Astrazeneca, up from $382.0 million in the prior quarter.
• The five-year high for Short-term Investments was $4.5 billion in Q4 2023, with the low at -$93.0 million in Q4 2022.
• Average Short-term Investments over 5 years is $477.2 million, with a median of $211.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Short-term Investments plunged 191.18% in 2022, then soared 4954.84% in 2023.
• Over 5 years, Short-term Investments stood at -$93.0 million in 2022, then jumped by 4954.84% to $4.5 billion in 2023, then plunged by 95.97% to $182.0 million in 2024, then surged by 173.63% to $498.0 million in 2025, then declined by 20.88% to $394.0 million in 2026.
• The last three Short-term Investments figures came in at $394.0 million (Q2 2026), $382.0 million (Q1 2026), and $498.0 million (Q4 2025), per Business Quant data.